← Eichor
Condition: Recurrent Or Metastatic Lung Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Or Metastatic Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994RGL-270 + ICI in Advanced NSCLC
NA · 1 location(s) · Guangdong Association of Clinical Trials · NCT07652125Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC
Phase 2 · 7 location(s) · Advenchen Pharmaceuticals, LLC. · NCT05363280A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Phase 2 · 5 location(s) · Dwight Owen · NCT04919382TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06538012SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · University of Washington · NCT05570825A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · 39 location(s) · AstraZeneca · NCT07357597CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06532799Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 · 71 location(s) · Iovance Biotherapeutics, Inc. · NCT04614103Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NA · 6 location(s) · A.O.U. Città della Salute e della Scienza · NCT05689619Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Pa
Phase 2 · 1 location(s) · Li-kun Chen · NCT06728852PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT05234307Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 · 8 location(s) · Orano Med Theranostics, SAS · NCT05283330A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.